Two Sigma Investments LP cut its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,420,403 shares of the biopharmaceutical company's stock after selling 8,933 shares during the period. Two Sigma Investments LP owned approximately 0.41% of Royalty Pharma worth $61,744,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also made changes to their positions in the stock. Adage Capital Partners GP L.L.C. grew its position in shares of Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after purchasing an additional 5,069,127 shares in the last quarter. Swedbank AB grew its position in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after purchasing an additional 1,136,800 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Royalty Pharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock valued at $186,846,000 after purchasing an additional 46,765 shares in the last quarter. Norges Bank purchased a new stake in shares of Royalty Pharma in the fourth quarter valued at approximately $124,498,000. Finally, Northern Trust Corp grew its position in shares of Royalty Pharma by 12.8% in the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock valued at $84,959,000 after purchasing an additional 376,619 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
Royalty Pharma Trading Up 0.7%
RPRX opened at $34.25 on Tuesday. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.50. The stock has a market capitalization of $19.74 billion, a PE ratio of 23.62, a P/E/G ratio of 2.31 and a beta of 0.49. The business's 50 day moving average price is $32.42 and its 200 day moving average price is $30.06. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. As a group, equities research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is 47.57%.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Monday, May 12th. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday. They issued an "overweight" rating and a $51.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and an average target price of $42.50.
Get Our Latest Analysis on Royalty Pharma
Royalty Pharma Company Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
